Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07663279

BicMag Study - Improving Mineral Buffering Capacity in Dialysis Patients

The BicMag study is a prospective, randomized, controlled cross-over study that aims to examine the potential additive effect of a dialysate enriched with both bicarbonate and magnesium on mineral buffering capacity in the blood of chronic hemodialysis patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

We hypothesize that simultaneously increasing bicarbonate and magnesium concentrations in the dialysate will enhance mineral buffering capacity more effectively than either intervention alone. Ninty-one chronic hemodialysis patients will be enrolled in this randomized, controlled, cross-over study. Using a balanced Latin square design, participants will undergo four sequential 3-week treatment phases with the following dialysates:

  • D-Standard: 32 mmol/L bicarbonate, 0.5 mmol/L magnesium
  • D-Bic: 37 mmol/L bicarbonate, 0.5 mmol/L magnesium
  • D-Mag: 32 mmol/L bicarbonate, 1 mmol/L magnesium
  • D-BicMag: 37 mmol/L bicarbonate, 1 mmol/L magnesium. The primary endpoint is calciprotein crystallization time (T50); the secondary endpoint is serum levels of endogenous calciprotein particles.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Prevalent patients (≥ 3 months) treated with thrice weekly hemodialysis or hemodiafiltration
  • Dialysate calcium of 1.25 mmol/l

Exclusion criteria

  • Inability to provide informed consent
  • Currently participating in another investigational device or drug study or non-interventional study
  • Dialysate calcium other than 1.25 mmol/l
  • Parathyroidectomy planned during the study
  • Elective living-donor kidney transplant scheduled during the study period
  • Therapy with bisphosphonates within the past 12 months or denosumab within the past 6 months
  • Pregnant or nursing (lactating) women

Treatment and study plan

D-Standard

Other

Center's standard dialysate containing 32 mmol/L bicarbonate and 0.5 mmol/L magnesium

D-Bic

Other

Dialysate bicarbonate increased to 37 mmol/L; dialysate magnesium held at 0.5 mmol/L

D-Mag

Other

Dialysate magnesium increased to 1.0 mmol/L; dialysate bicarbonate held at 32 mmol/L

D-BicMag

Other

Dialysate bicarbonate increased to 37 mmol/L; dialysate magnesium increased to 1.0 mmol/L

Primary outcomes

  1. Calciprotein crystallization time (T50) as a measure of mineral buffering capacity

    Time frame: 3 weeks (per study phase)

    Intra-individual difference in T50 between the combination dialysate (D-BicMag) and each of the single-intervention dialysates (D-Bic and D-Mag)

Secondary outcomes

  1. Endogenous calciprotein particle (CPP) levels

    Time frame: 3 weeks (per study phase)

    Intra-individual difference in endogenous calciprotein particle levels between the combination dialysate (D-BicMag) and each of the single-intervention dialysates (D-Bic and D-Mag)

Sponsors and collaborators

Lead sponsor

Elisabethinen Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 23, 2026
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.